{"id":5516,"date":"2025-01-23T18:48:21","date_gmt":"2025-01-23T15:48:21","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5516"},"modified":"2025-01-23T18:48:21","modified_gmt":"2025-01-23T15:48:21","slug":"by-the-end-of-2024-tavr-studies","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/by-the-end-of-2024-tavr-studies\/","title":{"rendered":"By the end of 2024 TAVR studies"},"content":{"rendered":"
By the end of 2024 TAVR studies:<\/div>\n
1-Years of Progress Have Made TAVR More Effective When Treating Concomitant Mitral Stenosis by the End of 2024<\/div>\n
<\/div>\n
A recent study published in Circulation: Cardiovascular Interventions highlights significant advancements in transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis (AS) and severe mitral stenosis (MS). Using modern balloon-expandable valves, such as the SAPIEN 3 Ultra Resilia, TAVR has become safer and more effective for high-risk patients, overcoming previous challenges in treating both conditions simultaneously.<\/div>\n
<\/div>\n
The study analyzed data from over 200,000 TAVR patients (2015\u20132022) from the TVT Registry.<\/div>\n
<\/div>\n
https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.124.014216<\/a><\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
2- Off-Label TAVR for Native Aortic Regurgitation Linked to Worse Outcomes<\/div>\n
<\/div>\n
A meta-analysis published in JACC: Cardiovascular Interventions shows that using off-label TAVR devices designed for aortic stenosis (AS) to treat pure native aortic regurgitation (AR) results in significantly worse outcomes compared to using devices specifically designed for AR.<\/div>\n
<\/div>\n
Key Findings:<\/div>\n
1. Higher Mortality Rates:<\/span><\/div>\n
\u2022 30-day mortality: 9% with off-label devices vs. 3% with dedicated AR devices.<\/span><\/div>\n
\u2022 One-year mortality: 24% with off-label devices vs. 6% with AR-specific devices.<\/span><\/div>\n
2. Device Performance:<\/span><\/div>\n
\u2022 Dedicated AR devices (e.g., JenaValve Trilogy, J-Valve) had higher success rates (93% vs. 82%) and lower risks of reintervention, valve embolization, and moderate\/severe residual AR.<\/span><\/div>\n
\u2022 Fewer complications with dedicated devices:<\/span><\/div>\n
\u2022 Pacemaker implantation: 11% vs. 20%.<\/span><\/div>\n
\u2022 Major bleeding: 3% vs. 7%.<\/span><\/div>\n
3. Comparing JenaValve and J-Valve:<\/span><\/div>\n
\u2022 JenaValve was associated with a lower pacemaker rate (6% vs. 21%) and better residual AR outcomes compared to J-Valve.<\/span><\/div>\n
<\/div>\n
Conclusion:<\/div>\n
<\/div>\n
Dedicated TAVR devices for AR, such as JenaValve and J-Valve, address anatomical challenges like aortic root dilation and lack of calcification more effectively than off-label AS devices. The study strongly supports prioritizing AR-specific valves for this high-risk population to improve outcomes and reduce complications.<\/div>\n
<\/div>\n
https:\/\/www.jacc.org\/doi\/10.1016\/j.jcin.2024.08.042<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

By the end of 2024 TAVR studies: 1-Years of Progress Have Made TAVR More Effective When Treating Concomitant Mitral Stenosis by the End of 2024 A recent study published in Circulation: Cardiovascular Interventions highlights significant advancements in transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis (AS) and severe mitral stenosis (MS). Using […]<\/p>\n","protected":false},"author":1,"featured_media":5518,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5516"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5516\/revisions"}],"predecessor-version":[{"id":5520,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5516\/revisions\/5520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}